CA2978965C - 1-((n-(2benzyl-phenyl)-carbamoyl-methyl)-carbamoyl)-naphthalene as anticancer therapeutic agent - Google Patents

1-((n-(2benzyl-phenyl)-carbamoyl-methyl)-carbamoyl)-naphthalene as anticancer therapeutic agent Download PDF

Info

Publication number
CA2978965C
CA2978965C CA2978965A CA2978965A CA2978965C CA 2978965 C CA2978965 C CA 2978965C CA 2978965 A CA2978965 A CA 2978965A CA 2978965 A CA2978965 A CA 2978965A CA 2978965 C CA2978965 C CA 2978965C
Authority
CA
Canada
Prior art keywords
cancer
compounds
capcna
compound
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2978965A
Other languages
English (en)
French (fr)
Other versions
CA2978965A1 (en
Inventor
Robert J. Hickey
Linda H. Malkas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RLL LLC
Original Assignee
RLL LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RLL LLC filed Critical RLL LLC
Publication of CA2978965A1 publication Critical patent/CA2978965A1/en
Application granted granted Critical
Publication of CA2978965C publication Critical patent/CA2978965C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2978965A 2015-04-10 2016-04-08 1-((n-(2benzyl-phenyl)-carbamoyl-methyl)-carbamoyl)-naphthalene as anticancer therapeutic agent Active CA2978965C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/684,259 US10420840B2 (en) 2015-04-10 2015-04-10 Anticancer therapeutic agents
US14/684,259 2015-04-10
PCT/US2016/026619 WO2016164707A1 (en) 2015-04-10 2016-04-08 Anticancer therapeutic agents

Publications (2)

Publication Number Publication Date
CA2978965A1 CA2978965A1 (en) 2016-10-13
CA2978965C true CA2978965C (en) 2023-11-14

Family

ID=57072079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978965A Active CA2978965C (en) 2015-04-10 2016-04-08 1-((n-(2benzyl-phenyl)-carbamoyl-methyl)-carbamoyl)-naphthalene as anticancer therapeutic agent

Country Status (12)

Country Link
US (1) US10420840B2 (https=)
EP (2) EP3280261B1 (https=)
JP (1) JP6748704B2 (https=)
CN (1) CN107404876B (https=)
AU (1) AU2016245886B2 (https=)
BR (1) BR122023024844A2 (https=)
CA (1) CA2978965C (https=)
ES (1) ES2991018T3 (https=)
FI (1) FI3878444T3 (https=)
PL (2) PL3878444T3 (https=)
PT (1) PT3878444T (https=)
WO (1) WO2016164707A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250171404A1 (en) * 2022-03-07 2025-05-29 City Of Hope Pcna inhibitors and uses thereof
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
MX2007013584A (es) 2005-04-27 2008-04-22 Univ Indiana Res & Tech Corp Anticuerpos de isoforma de cspcna y sus usos.
AU2006261856B2 (en) * 2005-06-27 2012-07-05 Indiana University Research And Technology Corporation csPCNA isoform modifications and uses thereof
CA2638866C (en) * 2006-02-17 2015-11-10 Indiana University Research And Technology Corporation Peptide based inhibition of capcna protein-protein interactions in cancer
US20090123487A1 (en) 2007-09-19 2009-05-14 Katia Rothhaar Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA3023068C (en) * 2008-07-24 2022-06-21 Indiana University Research And Technology Corporation Cancer peptide therapeutics
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
CN103619331A (zh) * 2011-03-23 2014-03-05 印第安纳大学研究及科技公司 抗癌治疗剂
EP3349754B9 (en) * 2015-09-17 2025-10-22 City of Hope Pcna inhibitors

Also Published As

Publication number Publication date
EP3280261B1 (en) 2020-12-23
BR122023024844A2 (pt) 2024-01-23
EP3280261A4 (en) 2018-12-12
PT3878444T (pt) 2024-11-08
CA2978965A1 (en) 2016-10-13
BR112017019983A2 (pt) 2018-06-19
PL3280261T3 (pl) 2021-09-06
WO2016164707A1 (en) 2016-10-13
PL3878444T3 (pl) 2025-01-07
US10420840B2 (en) 2019-09-24
ES2991018T3 (es) 2024-12-02
EP3878444A1 (en) 2021-09-15
US20160296482A1 (en) 2016-10-13
AU2016245886A1 (en) 2017-10-12
CN107404876A (zh) 2017-11-28
EP3280261A1 (en) 2018-02-14
JP6748704B2 (ja) 2020-09-02
FI3878444T3 (fi) 2024-11-19
AU2016245886B2 (en) 2020-04-30
JP2018510917A (ja) 2018-04-19
EP3878444B1 (en) 2024-10-09
CN107404876B (zh) 2023-04-14

Similar Documents

Publication Publication Date Title
JP2017141269A (ja) 乳がんの処置
TW202207939A (zh) 單一療法及組合療法
KR20210095721A (ko) 인돌리논 화합물의 용도
CA2978965C (en) 1-((n-(2benzyl-phenyl)-carbamoyl-methyl)-carbamoyl)-naphthalene as anticancer therapeutic agent
BR112012019691B1 (pt) Métodos in vitro para reduzir a atividade de uma proteína, ou para alterar a progressão do ciclo celular eucariótico, composto para a inibição de rpa, seus usos e uso de um composto a ou um sal farmaceuticamente aceitável do mesmo
EP2890374B1 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
US20130345231A1 (en) Anticancer therapeutic agents
ES2689665T3 (es) Compuestos y métodos para tratar la leucemia
WO2013138600A1 (en) Radioprotector compounds
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40058784A (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
JP2003532669A (ja) 高濃度グルタチオンを伴う腫瘍の治療における置換アクリロイルディスタマイシン誘導体の使用
WO2023175615A1 (en) Arts mimetic componds and combinations thereof for treating high-risk neuroblastoma
HK1246085B (en) Anticancer therapeutic agents
US8293764B2 (en) Compositions and methods for disruption of BRCA2-Rad51 interaction
BR112017019983B1 (pt) Agentes terapêuticos anticâncer
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
EP3624798A1 (en) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN112999236A (zh) 乌本苷用于治疗脑干胶质瘤的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210205

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404